Evaluation of Vepoloxamer in Chronic Heart Failure

Stopped early · Phase 2

Conditions studied: Chronic Heart Failure

In brief

The purpose of this study is to evaluate whether vepoloxamer can provide a blood chemical marker and functional benefit to damaged heart muscle cells. This will be evaluated by measurement of blood-based laboratory markers, exercise tolerance, and echocardiograms. In addition, the safety and blood levels of vepoloxamer in subjects with chronic heart failure will be evaluated.

Key facts

Study ID

NCT02596477

Run by

Mast Therapeutics, Inc.

People needed

10

Starts

2015-10-01

Last updated by the study team

2016-10-28

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 through 74
• Duration of documented heart failure >3 months
• On stable concomitant medication regimen ≥4 weeks
• Left ventricular ejection fraction ≤35%
• Systolic blood pressure ≥90 mmHg

You may not qualify if…

• Severe valvular stenosis or primary valvular regurgitation as the cause of heart failure
• History of myocardial infarction, coronary artery bypass graft surgery, or percutaneous intervention within the prior 3 months
• Estimated glomerular filtration rate ≤45 mL/min/1.73 m2
• Acutely decompensated heart failure within 1 month prior to the screening visit

Where it is running

• Research Center — Detroit, Michigan, United States
• Research Center — Tupelo, Mississippi, United States
• Research Center — Cardiff, New South Wales, Australia
• Research Center — Melbourne, Victoria, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.